Intrinsic Value of S&P & Nasdaq Contact Us

Glaukos Corporation GKOS NYSE

NYSE • Healthcare • Medical - Devices • US • USD

SharesGrow Score
52/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$143.44
+18.5%

Glaukos Corporation (GKOS) reported total assets of $893.49M and total liabilities of $237.33M for quarter ending 2025-12-31, resulting in total equity of $656.16M.

The company held $278.76M in cash and short-term investments. Total debt stood at $139.64M, with net debt of $48.83M. The Debt-to-Equity (D/E) ratio was 0.21 (conservative).

Current ratio is 4.69, indicating strong short-term liquidity. Interest coverage is -16.1x (weak).

Criteria supported by this page:

  • HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
  • MOAT (55/100) — Total assets $893.49M and equity $656.16M support the company's competitive scale
  • VALUE (92/100) — Debt-to-Equity 0.21 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 52/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score
52/100
SG Score
View full scorecard →
VALUE
92/100
Price-to-Earnings & upside
→ Valuation
FUTURE
79/100
Analyst consensus
→ Forecast
PAST
0/100
→ Income
~
HEALTH
67/100
Debt-to-Equity & liquidity
Proven by this page
~
MOAT
55/100
Proven by this page
~
GROWTH
58/100
→ Income
INCOME
10/100
→ Income
Glaukos Corporation Balance Sheet History
Metric Q4 FY2025 Q3 FY2025 Q2 FY2025 Q1 FY2025
Total Assets $893.49M$999.38M$986.96M$966.18M
Total Liabilities $237.33M$229.84M$221.85M$202.22M
Total Debt $139.64M$104.32M$105.02M$105.48M
Cash & Investments $278.76M$273.71M$274.79M$298.7M
Total Stockholders Equity $656.16M$769.54M$765.11M$763.96M
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message